Table 2 Baseline characteristics of two groups
Variable | Group A Before COVID period (April 2019–April 2020) | Group B COVID period (May 2020–May 2021) | p-value | ||
|---|---|---|---|---|---|
Age (mean) | 51.18 | - | 48.33 | - | < 0.05 |
Gender | |||||
 Female | 512 | 53% | 335 | 54% | 0.72 |
 Male | 447 | 47% | 282 | 46% | |
Comorbidity | |||||
 Diabetes | 42 | 4.3% | 31 | 5% | 0.8 |
 Hypertension | 77 | 8% | 49 | 7.9% | |
 Other | 26 | 2.7 | 15 | 2.4% | |
ECOG | |||||
 1 | 959 | 100% | 617 | 100 | NC |
T stage | |||||
 1 | 34 | 3.5% | 9 | 1.4% | 0.04 |
 2 | 248 | 25.8% | 146 | 23.6% | |
 3 | 341 | 35.5% | 242 | 39.3% | |
 4 | 336 | 35% | 220 | 35.6% | |
N stage | |||||
 0 | 440 | 45.8% | 246 | 39.8% | 0.01 |
 N+ | 519 | 54.2% | 371 | 60.2% | |
M stage | |||||
 0 | 959 | 100% | 617 | 100% | NC |
Neoadjuvant treatment | |||||
 Yes | 289 | 30% | 184 | 29.8% | 0.89 |
 No | 670 | 70% | 433 | 70.2% | |